TABLE 4.
Study | Availability of the primary outcome measure(s) (%) | Treatment exposure (%) | Attendance at follow-up visits (%) |
---|---|---|---|
CTN0001-BUP1 inpatient | 40 | 74 | 69 |
CTN0002-BUP2 outpatient | 59 | 73 | 61 |
CTN0003-BUP3 taper | 72 | 79 | 47 |
CTN0004-MET | 53 | 69 | 68 |
CTN0005-MI | 64 | 89 | 76 |
CTN0006-MIEDAR drug-free | 60 | 88 | 69 |
CTN0007-MIEDAR methadone | 77 | 95 | 83 |
CTN0009-smoking | 81 | 82 | 79 |
CTN0010-BUP adolescent | 62 | 88 | 61 |
CTN0011-TELE | 71 | 56 | 72 |
CTN0013-MET pregnant | 98 | 71 | 77 |
CTN0014-BSFT | 76 | 59 | 73 |
CTN0015-seeking safety | 611 | 54 | 61 |
CTN0017-HIV | 71 | 77 | 64 |
CTN0018-safe sex for men | 78 | 50 | 71 |
CTN0019-safe sex for women | 75 | 45 | 67 |
CTN0020-job seekers | 86 | 59 | 84 |
CTN0021-Spanish MET | 88 | 75 | 82 |
CTN0027-START | 67 | 64 | 47 |
CTN0028-ADHD adolescent | 862 | 80 | 71 |
CTN0029-ADHD adult | 87 | 91 | 82 |
CTN0030-POATS phase II | 92 | 76 | 60 |
CTN0031-STAGE12 | 80 | 67 | 70 |
CTN0032-HIV rapid testing | 983 | 100 | 96 |
Notes: PTSD, Post-Traumatic Stress Disorder; ADHD, Attention Deficit Hyperactivity Disorder.
For CTN0015, there were two co-primary endpoints: drug use (61%) and PTSD severity (61%). The analysis used drug use only.
For CTN0028, there were two co-primary endpoints: drug use (86%) and ADHD (76%). The analysis used drug use only.
For CTN0032, there were two co-primary endpoints: receipt of HIV test result at 1 month (98%) and risky sexual behaviors at 6 months (89%). The analysis used receipt of HIV test result only.